Immuron (IMC: $0.075) has reported a record $1.5 million in sales in the September quarter for its Travelan product used to prevent travelers' diarrhea.

The FDA has removed a clinical hold on Immuron's (IMC: $0.08) study for a new therapeutic to prevent infectious diarrhea, caused by two bacteria, E. coli and Campylobacter.

Immuron's (IMC: $0.078) business was severely impacted by the pandemic, with its lead product, Travelan, sold to prevent traveller's diarrhea. Sales fell from $2.7 million in FY2020 to just $166,000 in FY2021.